Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, 18 to 75 years of age inclusive
Body weight \>/= 40 kg
Physician's diagnosis of asthma for at least 12 months
Evidence of documented bronchodilator reversibility as defined by protocol
Prebronchodilator FEV1 \>/= 40% and \</= 80% predicted at Visit 1
Required daily use of ICS and a second controller for a minimum of 3 consecutive months prior to Visit 1
History of at least one protocol-defined asthma exacerbation in the 18 months prior to Visit 1
Inadequately controlled asthma despite compliance with asthma controller therapy
You may not be if
Asthma exacerbation requiring systemic steroids in the 30 days prior to Visit 1
Pre-existing active lung disease other than asthma
Any infection
Clinically significant medical disease that is uncontrolled despite treatment or is likely to require a change in therapy during study or is of unknown etiology
Known immunodeficiency, including but not limited to HIV infection, regardless of treatment status
Current substance abuse
Former smoker with \>10 pack-year history or current smoker; former smokers must have stopped smoking more than 12 months prior to Visit 1
History of anaphylaxis
Pregnant and lactating women
Clareo Health | A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)
